Immune recognition and clearance of hepatitis B virus (HBV) infected hepatocytes in chronic HBV infection is believed to result from the T lymphocyte response to viral antigens associated with human class I major histocompatibility complex molecules.'-3 The observation that a successful response to interferon-a (IFNa) therapy is heralded by a hepatitis-like illness occurring eight to 12 weeks after the start of treatment further supports the role of the immune system in the virus-host interaction.'4 HBV infection is also related to a variety of immunoregulatory defects including deficient IFNa and IFNy production,5 6 resistance to IFNs,'7 and dysfunction of peripheral blood monocytes associated with abnormal T cell activation. 8 The production of tumour necrosis factor-a (TNFa) by peripheral blood mononuclear cells (PBMCs) has been shown to be increased in patients with chronic HBV infection. 9 The expression of TNFa receptor on PBMC was also increased despite raised circulating TNFa concentrations.'0 In patients with chronic HBV infection who responded successfully to IFNa treatment there was a marked spontaneous production of TNFa by PBMCs during the e-seroconversion period which was not observed in non-responders." Whether local production of TNFa in the liver tissue in chronic HBV infection is increased or not has yet to be established. The purpose of the present study was to determine the intrahepatic expression 13 The specimens obtained by percutaneous liver biopsy were divided into two parts: one part was fixed in 10% formaldehyde and processed for routine histological studies, the other part was snap-frozen in liquid nitrogen cooled isopentane. Cryostat liver tissue sections (5 ,m) were then prepared on slides previously coated with 0-1% poly-l-lysine
agcyopas wer positive fo TNa Noeta oeo4hs NF oiieclsaei loua ara ( x ib~~~~~~~~~~~~~~~~~i (Sigma, Dorset, UK) to enhance attachment.'4 The sections were dried overnight at room temperature, wrapped individually with aluminum foil, and stored at -20°C. After thawing on the day of the experiment, the sections were fixed in acetone for five minutes and extensively washed with phosphate buffered saline (PBS; pH 7 4).
After inactivating the endogenous peroxidase activity with methanol containing 0 3% hydrogen peroxide, the sections were covered with 5% normal rabbit serum (NRS; Dako, Bucks, UK) and 3% bovine serum albumin (BSA) in PBS for 15 minutes to block nonspecific absorption. TNFa was then sought using mouse monoclonal antibodies to TNFa diluted 1 in 10 in PBS for one hour at room temperature (anti-TNFa, cell clone 357-27-2; kind gift of Dr A Meager, Mill Hill, UK). The concentration of monoclonal antibody used was 50 ,ug/ml. After washing with PBS, the sections were incubated with horseradish peroxidase conjugated rabbit anti-mouse antibody (Serotec, Oxford, UK), at a dilution of 1 in 50 in PBS, for one hour at room temperature. Diaminobenzidine (0 5 mg/ml) containing 0 01% hydrogen peroxide was used as the substrate (for 10 minutes) and the sections were counterstained with haematoxylin, dehydrated in graded alcohol solutions and xylene, and mounted in DPX. In all experiments normal mouse serum was used in the first antibody layer to serve as a control to verify the specificity of the reaction. Each slide was individually assessed by two authors (MJH and JYNL), and the average score was used for analysis.
Expression Patients with raised serum aspartate aminotransferase (AST) activities also showed increased expression of TNFa (median 2, range 1-3; n = 12) compared with patients with normal serum AST activities (median 1, range 0-1; p < 0O01). There was no correlation between the levels of TNFa expression and serological markers of viral infection.
Discussion
The present study shows that intrahepatic expression of TNFa is increased in patients with chronic HBV infection and active liver disease compared with those with inactive liver disease. Our data are consistent with a previous study which also showed an increase in the expression of TNFa within the infiltrating mononuclear cells of patients with chronic HBV infection. ' The trigger for enhanced expression/production of TNFa in patients with chronic HBV infection and active liver disease remains unknown. It is possible that the induction of TNFa production is secondary to other events in the cytokine cascade. Interferon-y, a cytokine with a central role in inflammatory response, has been shown to induce the production of TNFa. 22 Recently, we have shown that hepatic expression of TNFa is also increased in patients with acute alcoholic hepatitis (Lau et al, 1994 , unpublished data). Enhanced expression of TNFa in another liver disease further supports the hypothesis that the trigger for the local production of TNFa is secondary to other inflammatory events and is unlikely to be specific to HBV infection.
